| 558. |
THE MATTEK STORY — HOW THE THREE Rs PRINCIPLES LED TO 3-D TISSUE SUCCESS!
|
| 531. |
ALTERNATIVE METHODS FOR PHOTOTOXICITY TEST USING RECONSTRUCTED HUMAN SKIN MODEL.
|
| 441. |
COMPARISON OF IN VITRO PHOTOTOXICITY TEST METHODS: 3T3 NRU PT VS. ENHANCED PHOTOTOXICITY SCREENING ASSAY IN RECONSTITUTED SKIN (EPARS).
|
| 412. |
IN VITRO SCREEN FOR PHOTOTOXICITY OPTIMIZED DRUG DEVELOPMENT USING A HIGHLY DIFFERENTIATED SKIN MODEL.
|
| 372. |
ECVAM FEASIBILITY STUDY: CAN THE PRE-VALIDATED IN VITRO SKIN MODEL PHOTOTOXICITY ASSAY BE UPGRADED TO QUANTIFY PHOTOTOXIC POTENCY OF TOPICAL PHOTOTOXINS?
|
| 371. |
IN VITRO SKIN EQUIVALENT MODELS FOR TOXICITY TESTING.
|
| 355. |
LONG TERM REPRODUCIBILITY OF EPIDERM, AN EPIDERMAL MODEL FOR DERMAL TESTING AND RESEARCH.
|
| 316. |
AN ASSESSMENT OF THE PHOTOTOXIC HAZARD OF A PERSONAL PRODUCT INGREDIENT USING IN VITRO ASSAYS.
|
| 306. |
A TIERED STRATEGY FOR IN VITRO PHOTOTOXICITY TESTING.
|
| 299. |
ASSESSMENT OF HUMAN SKIN IRRITATION: VALIDATION OF IN VITRO MODELS.
|
| 236. |
RECONSTITUTED 3-DIMENSIONAL HUMAN SKIN AS A NOVEL IN VITRO MODEL FOR STUDIES OF CARCINOGENESIS.
|
| 235. |
EXPRESSION OF PLACENTA GROWTH FACTOR
CYCLOOXYGENASE AND THYMUS-AND ACTIVATION-REGULATED CHEMOKINE IN THE EPIDERM IN VITRO HUMAN SKIN EQUIVALENT.
|
| 229. |
AVOCADO PHYTOSTEROLS DECREASE UVB-INDUCED PRO-INFLAMMATORY MEDIATORS.
|
| 224. |
EVALUATION OF THE USEFULNESS OF 3-D MODELS OF RECONSTITUTED HUMAN SKIN AND EPIDERMIS IN APPLICATIONS OF REGULATORY SKIN TOXICOLOGY: PREVALIDATION, VALIDATION, CATCH-UP VALIDATION, AND REGULATORY ACCEPTANCE.
|
| 217. |
EFFECTS OF ANTIOXIDANT INGREDIENTS ON HUMAN SKIN: FROM CELL CULTURE TESTING TO HUMAN CLINICAL TRIALS.
|
| 212. |
IN VITRO TESTING FOR PHOTOTOXIC POTENTIAL USING THE EPIDERM 3-D RECONSTRUCTED SKIN MODEL.
|
| 209. |
A REPRODUCIBLE SKIN MODEL FOR DERMAL SAFETY AND EFFICACY TESTING.
|
| 207. |
DERMATACS™ IN SITU APOTOSIS DETECTION KIT FOR SKIN CELLS AND TISSUES.
|
| 205. |
A REPRODUCIBLE, STRUCTURALLY APPROPRIATE SKIN MODEL FOR DERMAL SAFETY AND EFFICACY TESTING.
|
| 197. |
CHANGES IN CANCER-RELATED GENE EXPRESSION IN AN IN VITRO HUMAN SKIN MODEL FOLLOWING UVB-IRRADIATION.
|
| 193. |
LACK OF PHOTOTOXICITY OF COSMETIC FORMULATIONS CONTAINING GLYCOLIC ACID IN AN IN VITRO HUMAN SKIN MODEL.
|
| 192. |
PREVALIDATION OF THE EPIDERM PHOTOTOXICITY TEST (ED-PT).
|
| 188. |
THE PROTEASE-ACTIVATED RECEPTOR 2 REGULATES PIGMENTATION VIA KERATINOCYTE-MELANOCYTE INTERACTIONS.
|
| 181. |
PREVALIDATION OF THE EPIDERM PHOTOTOXCITY TEST.
|
| 173. |
NEW RESULTS WITH MELANODERM™, AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES.
|
| 172. |
PROTECTING THE SKIN AGAINST EXOGENOUS NOXES.
|
| 171. |
EPIDERMAL STRATIFICATION REDUCES THE EFFECTS OF UVB (BUT NOT UVA) ON KERATINOCYTE CYTOKINE PRODUCTION AND CYTOTOXICITY.
|
| 169. |
PREVALIDATION OF TESTS FOR PREDICTING SKIN CORROSIVITY AND PHOTOTOXICITY USING AN IN VITRO MODEL OF HUMAN EPIDERMIS.
|
| 164. |
ULTRAVIOLET B RADIATION UPREGULATES THE PRODUCTION OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN HUMAN EPIDERMAL KERATINOCYTES.
|
| 161. |
RECONSTITUTED 3-DIMENSIONAL HUMAN SKIN AS A NOVEL IN VITRO MODEL FOR STUDIES OF CARCINOGENESIS.
|
| 155. |
DEVELOPMENT OF A NEW IN VITRO TEST FOR DERMAL PHOTOTOXICITY USING A MODEL OF RECONSTITUTED HUMAN EPIDERMIS (EPIDERM).
|
| 150. |
RECONSTITUTED 3-DIMENSIONAL HUMAN SKIN, A NEW IN VITRO MODEL FOR SKIN CARCINOGENESIS STUDY.
|
| 143. |
PRESENCE OF HYDROCORTISONE DRAMATICALLY AFFECTS CYTOKINE PRODUCTION FOLLOWING UV IRRADIATION IN 3-DIMENSIONAL SKIN MODEL EPIDERM.
|
| 128. |
AN IN VITRO METHOD TO EVALUATE THE ANTIOXIDANT EFFICACY OF TOPICAL FORMULATIONS.
|
| 126. |
A COMPARISON STUDY OF FOUR IN VITRO PHOTOTOXICITY SYSTEMS.
|
| 122. |
INITIAL CHARACTERIZATION OF AN EPIDERMAL MODEL CONTAINING FUNCTIONAL MELANOCYTES.
|
| 121. |
CYTOKINE RESPONSE OF THE EPIDERM SKIN MODEL TO TOPICALLY APPLIED IRRITANTS AND TOXICANTS.
|
| 119. |
UVB IRRADIATION OF AN ORGANOTYPIC SKIN MODEL, EPIDERM™, RESULTS IN SIGNIFICANT RELEASE OF CYTOKINES.
|
| 116. |
USE OF THE MATTEK EPI-100 IN VITRO SYSTEM TO SCREEN ANTIOXIDANT EFFICACY.
|
